Oral and injectable formulations of existing drugs often exhibit poor bioavailability, systemic toxicity, and suboptimal patient adherence due to frequent dosing and adverse effects (e.g., gastrointestinal distress and rashes) (Sattui and Gaffo, 2016)
Common doses are 2 to 5 milligrams per week, split into 2 or 3 shots, for 4 to 8 weeks
At En Vogue IV Therapy & Wellness Clinic, we understand that managing type 2 diabetes and obesity requires not only effective treatment but also cost-effective solutions
Known as the "Triple G," it targets three vital metabolic pathways: the GLP-1 (Glucagon-like peptide-1), GIP (Glucose-dependent insulinotropic polypeptide), and GCG (Glucagon) receptors
In adults with type 1 diabetes and obesity, semaglutide treatment, compared with AID use alone, significantly improved achievement of a composite of time in range of greater than 70%, with time below range of less than 4%, and a 5% body weight reduction, concluded the authors.
The researchers conducted a retrospective cohort study to examine the association between use of GLP-1 RAs and the risk for dementia in patients with CKD stage 3 or later, compared with use of dipeptidyl peptidase-4 (DPP-4) inhibitors
